Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoembolization for lung metastases
NCT04200417Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitomycin c in lung metastases (LM), secondary malignant neoplasm of bronchus and lung, Pleural metastasis and 1 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Participant toxicity at 12 months. Started Dec 2019; status: completed.
02
Drugs
mitomycin c
03
Conditions
lung metastases (LM)secondary malignant neoplasm of bronchus and lungPleural metastasismetastasis
Beyond the preview
Go deeper on NCT04200417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04200417.